Overall Survival (Univariate Cox's Regression Model)
| Variable . | RL . | RR . | 95% CI . | P . |
|---|---|---|---|---|
| Clinical | ||||
| Age | <60 | 2.59 | 1.13-5.93 | .0226 |
| Gender | Female | 1.35 | 0.59-3.09 | .5266 |
| B-symptoms | Negative | 4.85 | 1.83-12.84 | .0016 |
| Stage III | I + II | 6.64 | 2.16-20.38 | .0011 |
| Stage IV | I + II | 8.54 | 2.71-26.87 | .0003 |
| Type | ||||
| NS | LP | 1.83 | 0.23-14.24 | .5678 |
| MC | NS | 4.02 | 0.52-30.58 | .1753 |
| LD | MC | 6.33 | 0.57-70.09 | .1277 |
| Immunohistochemistry | ||||
| CD 15 | Negative | 0.89 | 0.38-2.11 | .7990 |
| bcl.2 | Negative | 0.69 | 0.32-1.45 | .6655 |
| LMP1 | Negative | 0.85 | 0.40-1.80 | .6881 |
| Rb4-150 | 0 | 0.96 | 0.91-1.01 | .1540 |
| p534-150 | 0 | 0.95 | 0.85-1.06 | .6178 |
| Ki674-150 | 0 | 1.04 | 1.00-1.08 | .0206 |
| Variable . | RL . | RR . | 95% CI . | P . |
|---|---|---|---|---|
| Clinical | ||||
| Age | <60 | 2.59 | 1.13-5.93 | .0226 |
| Gender | Female | 1.35 | 0.59-3.09 | .5266 |
| B-symptoms | Negative | 4.85 | 1.83-12.84 | .0016 |
| Stage III | I + II | 6.64 | 2.16-20.38 | .0011 |
| Stage IV | I + II | 8.54 | 2.71-26.87 | .0003 |
| Type | ||||
| NS | LP | 1.83 | 0.23-14.24 | .5678 |
| MC | NS | 4.02 | 0.52-30.58 | .1753 |
| LD | MC | 6.33 | 0.57-70.09 | .1277 |
| Immunohistochemistry | ||||
| CD 15 | Negative | 0.89 | 0.38-2.11 | .7990 |
| bcl.2 | Negative | 0.69 | 0.32-1.45 | .6655 |
| LMP1 | Negative | 0.85 | 0.40-1.80 | .6881 |
| Rb4-150 | 0 | 0.96 | 0.91-1.01 | .1540 |
| p534-150 | 0 | 0.95 | 0.85-1.06 | .6178 |
| Ki674-150 | 0 | 1.04 | 1.00-1.08 | .0206 |
Abbreviations: RL, reference level; RR, risk ratio in specific disease mortality; CI, confidence intervals; LP, lymphocytic predominance; NS, nodular sclerosis; MC, mixed cellularity; LD, lymphocytic depletion.
Rb, p53, and Ki67 expression was analyzed as continuous variables.